An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant Patients
Public ClinicalTrials.gov record NCT01467505. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 2-Part, Open Label Study of Telaprevir in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Subjects Chronically Infected With Genotype 1 Hepatitis C Virus Following Liver Transplantation
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To assess efficacy of telaprevir, pegylated interferon alfa-2a (Peg-IFN-alfa-2a), and ribavirin (RBV) for hepatitis C virus (HCV) in a 48-week total treatment duration regimen following liver transplantation.
Study identification
- NCT ID
- NCT01467505
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 61 participants
Conditions and interventions
Conditions
Interventions
- Telaprevir Drug
- Ribavirin Drug
- Pegylated Interferon Alfa-2a Drug
- Immunosuppressant Regimen Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 2012 (Type not available)
- Primary completion
- Apr 2014 (Actual)
- Completion
- Apr 2014 (Actual)
- Last update posted
- Jun 18, 2015
2012 – 2014
United States locations
- U.S. sites
- 20
- U.S. states
- 16
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alabama | Birmingham | Alabama | — | — |
| Arizona | Phoenix | Arizona | — | — |
| California | Los Angeles | California | — | — |
| Colorado | Denver | Colorado | — | — |
| Florida | Bradenton | Florida | — | — |
| Florida | Miami | Florida | — | — |
| Illinios | Evanston | Illinois | — | — |
| Indiana | Indianapolis | Indiana | — | — |
| Massachusetts | Burlington | Massachusetts | — | — |
| Michigan | Ann Arbor | Michigan | — | — |
| Michigan | Detroit | Michigan | — | — |
| Missouri | St Louis | Missouri | — | — |
| Nebraska | Omaha | Nebraska | — | — |
| New York | New York | New York | — | — |
| New York | Rochester | New York | — | — |
| North Carolina | Charlotte | North Carolina | — | — |
| Ohio | Cleveland | Ohio | — | — |
| Pennsylvania | Philadelphia | Pennsylvania | — | — |
| Texas | Dallas | Texas | — | — |
| Texas | Houston | Texas | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01467505, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 18, 2015 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01467505 live on ClinicalTrials.gov.